Science Explorer Back to mapMap
Discussion
Researcher · Harbin Medical University · China

Gongyan Chen

Gongyan Chen publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Molecular Biology, on topics such as Lung Cancer Treatments and Mutations, Lung Cancer Research Studies and Lung Cancer Diagnosis and Treatment.

ORCID 0009-0003-8805-8812 OpenAlex
World rank
#188,061
of 7,710,434 ranked researchers
Rank in China
#18,792
of 978,568
Works
124
Citations
10k
Citations per work
82.6
h-index
33
i10-index 66Top 7.1% in Pulmonary and Respiratory Medicine
Gongyan Chen

What does Gongyan Chen research?

Gongyan Chen's work is mostly in Medicine (78%), Biochemistry, Genetics and Molecular Biology (8%).

Health Sciences: 97 works · 78.4% of their workMedicine: 97 works · 78.4% of their workPulmonary and Respiratory Medicine: 49 works · 39.5% of their workOncology: 41 works · 33.3% of their workSurgery: 4 works · 3.4% of their workPhysiology: 3 works · 2.2% of their workEverything else: 16 works · 13.3% of their workLife Sciences: 10 works · 8.3% of their workBiochemistry, Genetics and Molecular Biology: 10 works · 8.3% of their workMolecular Biology: 6 works · 4.9% of their workCancer Research: 4 works · 3.4% of their workTHEIR WORKGongyan Chen124works
Life Sciences8%Health Sciences78%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine9778.4%
  2. Everything else1613.3%
    1. Biochemistry, Genetics and Molecular Biology108.3%
  1. 1Pulmonary and Respiratory Medicine40% of their works
  2. 2Oncology33% of their works
  3. 3Molecular Biology5% of their works
  4. 4Surgery3% of their works
  5. 5Cancer Research3% of their works
  6. 6Physiology2% of their works

Research topics

Which keywords describe Gongyan Chen's research?

The keywords of their largest research topics: Targeted Therapy, Clinical Trials, Chemotherapy, ALK Inhibitors, EGFR Mutations, Genomic Profiles, Small-Cell Lung Cancer and Tumor Microenvironment.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Targeted Therapy1173 topics
  2. Clinical Trials1082 topics
  3. Chemotherapy803 topics
  4. ALK Inhibitors721 topic
  5. EGFR Mutations721 topic
  6. Genomic Profiles361 topic
  7. Small-Cell Lung Cancer361 topic
  8. Tumor Microenvironment312 topics
  9. CT Screening291 topic
  10. Lung Cancer291 topic
  11. Immune Checkpoint Blockade251 topic
  12. PD-1 and PD-L1251 topic
  13. Cetuximab151 topic
  14. KRAS Mutations151 topic
  15. Cancer Genomics91 topic
  16. Mutational Signatures91 topic
  17. Breast Cancer81 topic
  18. CDK4/6 Inhibitors81 topic
  19. Fibroblast Activation Protein61 topic
  20. Immunosuppression61 topic

Where does Gongyan Chen work?

Gongyan Chen's main affiliation in the publication record is Harbin Medical University, China.

How many publications and citations does Gongyan Chen have?

OpenAlex counts 124 works and 10,247 citations for Gongyan Chen, an h-index of 33, ranking #188,061 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Other researchers named Gongyan Chen

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Gongyan Chen. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.